Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Cinisello Balsamo – page 46

2 955 clinical trials in Cinisello Balsamo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Cinisello Balsamo at a glance
2 955
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

2 955 trials in Cinisello Balsamo

Open in trial search

Acarodermatitis

Recruiting

Comparing effectiveness of topical permethrin, oral ivermectin, and their combination for treating patients with confirmed scabies infection

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ivermectin
  • Sponsor:Giuliani S.p.A.

Bipolar I disorder+1

Recruiting

Long-term safety study of trospium chloride and xanomeline tartrate combination (KarXT) for treatment of manic episodes in adults with Bipolar I Disorder

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study of Mosunetuzumab Treatment in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mosunetuzumab
  • Sponsor:F. Hoffmann-La Roche AG

Study of momelotinib tablets in patients with anemia caused by low-risk myelodysplastic syndrome

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Cardiomyopathy

Recruiting

Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nucresiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:ETOP IBCSG Partners Foundation

Study comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Study of BMS-986504 for patients with advanced or metastatic non-small cell lung cancer with homozygous MTAP deletion who have previously received treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Navlimetostat
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of elacestrant and exemestane treatment for patients with previously treated hormone receptor-positive, HER2-negative metastatic breast cancer with FES-avid lesions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Study of RSV vaccine immune response persistence and revaccination safety in adult lung and kidney transplant recipients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:GSKVx000000017064
  • Sponsor:GlaxoSmithKline Biologicals

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ficerafusp alfa
  • Sponsor:Bicara Therapeutics Inc.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Cinisello Balsamo

What the registry says about research in the country

01 Mental Health Research

Innovative research focusing on Major Depressive Disorder with concurrent insomnia symptoms, evaluating new combination therapies alongside existing antidepressant treatments. Studies examine the effectiveness of adjunctive medications in improving depressive symptoms and sleep patterns.

  • Depression with Insomnia
  • Antidepressant Augmentation
  • Long-term Treatment Efficacy

Research aims to enhance treatment outcomes for patients who haven't responded adequately to conventional therapies.

02 Cardiovascular Studies

Advanced clinical research examining atherosclerotic cardiovascular disease prevention and treatment. Studies include innovative approaches to blood clot prevention in patients with irregular heartbeat who have undergone stent procedures.

  • Primary ASCVD Prevention
  • Anticoagulation Therapy
  • Post-PCI Treatment

Investigations focus on reducing major adverse cardiac events and improving patient outcomes.

03 Metabolic Disorders

Comprehensive studies targeting severe hypertriglyceridemia and related metabolic conditions. Multiple trials are evaluating new therapeutic approaches for managing elevated triglyceride levels and associated cardiovascular risks.

  • Triglyceride Management
  • Metabolic Disease Treatment
  • Cardiovascular Risk Reduction

Research focuses on developing effective treatments for patients with severe lipid disorders.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.